Elan Corporation, plc (ELN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Qualified Opinion who wrote (5119)	11/17/2003 1:56:34 PM
From: biostruggle	Read Replies (2) of 10345

I'm troubled by the AZ data. If the entire 300 patient study reveals similar results, that is patients whom generated ab were protected from further cognitive loss, then I can not understand why Wyeth-Elan are not pressing forward with AN-1792. A severe 2% side-effect with a disease that permanently destroys the mind is totally acceptable. CAncer patients take drugs with higher side-effect profiles and with less effect on disease progression. AN-1792 was in Phase II and should go to phase III, if these results hold. The so-called new vaccine and MoAB are years behind, even if they started Phase I now.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next